Expression of vascular endothelial growth factor by human eosinophils: Upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5

被引:180
作者
Horiuchi, T
Weller, PF
机构
[1] BETH ISRAEL DEACONESS MED CTR,DEPT MED,HARVARD THORNDIKE LABS,BOSTON,MA 02215
[2] BETH ISRAEL DEACONESS MED CTR,CHARLES A DANA RES INST,BOSTON,MA 02215
关键词
D O I
10.1165/ajrcmb.17.1.2796
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor (VEGF) is a pleiotropic polypeptide that mediates endothelial-cell-specific responses such as induction of proliferation and vascular leakage. We examined the expression of VEGF messenger RNA (mRNA) and protein by human eosinophils in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-5 (IL-5). Immunoreactive VEGF protein was detected in freshly isolated eosinophils by immunocytochemistry. Eosinophils spontaneously released VEGF protein in culture medium, and this release was upregulated by GM-CSF or IL-5. Freshly isolated eosinophils constitutively expressed VEGF mRNA. Although incubation of eosinophils in culture medium reduced steady-state VEGF mRNA levels, eosinophil VEGF mRNA levels were enhanced by GM-CSF and IL-5, and this enhancement was blocked by the transcription inhibitor actinomycin D. Analysis of alternatively spliced mRNA species revealed that eosinophils contained transcripts mainly encoding for the 121- and 165-amino-acid forms of VEGF. VEGF mRNA expression and VEGF release in cytokine-stimulated eosinophils were significantly reduced by treatment with a glucocorticosteroid, a protein-tyrosine kinase inhibitor, or a protein kinase C inhibitor. Cytokine-activated eosinophils may be an important source of a vascular permeability factor, namely VEGF, thus contributing to tissue edema formation at sites of allergic inflammation.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 43 条
[21]   CYTOKINE GENERATION BY EOSINOPHILS [J].
MOQBEL, R ;
LEVISCHAFFER, F ;
KAY, AB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (06) :1183-1188
[22]  
Nakajima H, 1996, J IMMUNOL, V156, P4859
[23]   EOSINOPHILS AS A POTENTIAL SOURCE OF PLATELET-DERIVED GROWTH-FACTOR B-CHAIN (PDGF-B) IN NASAL POLYPOSIS AND BRONCHIAL-ASTHMA [J].
OHNO, I ;
NITTA, Y ;
YAMAUCHI, K ;
HOSHI, H ;
HONMA, M ;
WOOLLEY, K ;
OBYRNE, P ;
DOLOVICH, J ;
JORDANA, M ;
TAMURA, G ;
TANNO, Y ;
SHIRATO, K .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (06) :639-647
[24]  
PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
[25]  
POWELL PP, 1993, AM J PATHOL, V143, P784
[26]  
ROGER DF, 1991, BR MED B, V48, P120
[27]   THE EFFECTS OF GLUCOCORTICOIDS ON HUMAN EOSINOPHILS [J].
SCHLEIMER, RP ;
BOCHNER, BS .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (06) :1202-1213
[28]  
SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244
[29]   INHIBITION OF PROGRAMMED EOSINOPHIL DEATH - A KEY PATHOGENIC EVENT FOR EOSINOPHILIA [J].
SIMON, HU ;
BLASER, K .
IMMUNOLOGY TODAY, 1995, 16 (02) :53-55
[30]   ASTHMA, INFLAMMATION, EOSINOPHILS AND BRONCHIAL HYPERRESPONSIVENESS [J].
SMITH, H .
CLINICAL AND EXPERIMENTAL ALLERGY, 1992, 22 (02) :187-197